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expression in brain causes abnormalities in cell architecture and
leads to severe neurological disorders.1,6,11 Oncogenic transforma-
tions and some other pathological processes in cells/tissues are
accompanied by changes in GSL metabolism and consequently,
their impaired composition/expression at the cell surface directly
affects cellular phenotype.12–17
Due to high structural diversity of both oligosaccharide and cer-
amide portion, GGs and sulfated GSLs are complex groups of glyco-
lipids. Based on difference in structure of carbohydrate portion,
more than 180 ganglioside species have been identiﬁed in verte-
brates so far. Taking into consideration the heterogeneity in the
ceramide part, the number of species increases manifold.1 GSL
structural identity is strictly related to their functional properties
as cell ligands and biomarkers.2,18 Elucidation of GSLs structure-
to-function relationships requires highly sensitive methods capa-
ble of detailed structural characterization. As GSLs are members
of both glycome and lipidome, various analytical approaches for
their analysis have been established among which mass spectrom-
etry (MS) methods became unavoidable. During last three decades
MS strategies for GSL characterization are constantly being devel-
oped and improved.16,17,19–24 Although MS and tandem MS
approaches to generate spectral data have been successful, data
analysis and interpretation still remains demanding and time con-
suming. Employment of MS for comparative compositional and
structural characterization of complex GSL mixtures isolated from
tissues and other biological material11,15,17,24–29 demands interpre-
tation and comparison of large amount of data, in order to investi-
gate their involvement/role and biomarker potential in
physiological/biological processes in health and diseases. There-
fore, researchers in glycolipidomics and biomedicine ﬁelds seek
for assistance of applicable software tools.
Currently, a considerablenumberof databases and software tools
for mass spectrometric data analysis and structural identiﬁcation of
various glycoconjugate and lipid classes are available.30–34However,
coverage of GSLs is mostly not comprehensive enough, so require-
ment for more complete GSL characterization tools has been recog-
nized. LIPID MAPS33 and SysBio Ware glycomics software
platform,34 as very useful tools, cover wide range of different GSL
structures, but still have some limitations that may be restrictive
for detailed characterization of complex GG and/or sulfo-GSL mix-
tures. For example, both databases do not include species that are
O-acetylated, de-N-acetylated, glucuronosylated nor various possi-
ble lactone forms. Glycosphingolipids containing such structural
modiﬁcations are nowadays in research focus as they are often
observed in pathologically changed versus healthy tissues. For
example, many different tumor types contain O-acetylated and de-
N-acetylated GG structures.35,36 Also, LIPIDMAPS do not offer possi-
bility to analyze more than one tandemMS spectrum at the time.
To facilitate efforts toward new GSL characterization tools, in
the present paper we demonstrate a computational GSL ion data-
base for negative ion MS and MSMS ion spectra search. The data-
base includes GGs and sulfo-GSLs as well as their neutral GSL
counterparts. For comparing experimental MS data with those
from the established database an application (GSL-ﬁnder) has been
developed. Finally, we test and evaluate the database and GSL-ﬁn-
der on a commercially available GG fraction as well as on a com-
plex native GG mixtures isolated from human (fetal and adult)
and calf brain tissues.
2. Materials and methods
2.1. Ganglioside samples
Puriﬁed GD1a ganglioside fraction (disialoganglioside-GD1a,
from bovine brain, minimum 95% TLC) was purchased from
Sigma–Aldrich (St Louis, USA). The native GG mixture analyzed
in this study was isolated from fetal human brain (gestational
age: 13 weeks). The GG mixture was extracted from brain tissue
according to the method of Svennerholm and Fredman37 and mod-
iﬁed by Vukelic´ et al.11 Lipids were extracted and re-extracted from
the homogenized brain tissue using a chloroform/methanol/water
mixture (1:2:0.75, by volume). To separate GGs from other lipids,
the lipid extract was subjected to a phase partition and upper
phases containing polar GSLs were collected. The crude GG extract
was puriﬁed by precipitation and gel ﬁltration on a Sephadex G-25
(Sigma–Aldrich, St Louis, USA) column. To preserve possible phys-
iologically relevant alkali-labile species, no alkali hydrolysis step
was performed during puriﬁcation. The pure extract was evapo-
rated and stored at 20 C. Permission for experiments with
human brain tissue for scientiﬁc purposes was obtained from the
Ethics Commission of the Zagreb School of Medicine, under the
Project No. 108-1081870-2415.2.2. Mass spectrometry
Analysis of GG samples was performed on a Bruker amaZon ETD
ion trap system (Bruker Daltonik GmbH, Bremen, Germany)
equipped with Apollo electrospray ionization source. Samples
were dissolved in methanol to obtain 1.6 lM concentration of
GG-bound sialic acids and introduced into the electrospray ioniza-
tion source by direct infusion at a ﬂow rate of 65 lL/h. The capil-
lary voltage was set at 4500 V while high voltage end plate offset
was 500 V. The temperature and ﬂow rate of the drying gas were
set at 210 C and 5 L/min, respectively. The electrospray ionization
source parameters were optimized to allow an efﬁcient ionization
and to reduce the in-source fragmentation of molecular ions. Puri-
ﬁed GD1a ganglioside fraction was used to test in-source fragmen-
tation. During MS acquisition no desialylation artifacts such as
GM1 or GA1 were observed. Helium was used as the collision
gas. The isolation width of the precursor ion was set at 0.5–1 Da.
The CID excitation time was 40 ms and the amplitude was in the
0.4–1 V range. All spectra were acquired in the negative ion mode
using a scan range from m/z 280 to 3000. Data Analysis software
4.0 (Bruker Daltonik GmbH, Bremen, Germany) was used for anal-
ysis (charge deconvolution and data reduction) and extraction of
the MS and MSMS data.
2.3. Algorithm and applications
The algorithm for in silico generation of GSL database was writ-
ten in Mathematica 8.0 (Wolfram Research Inc.). Several count and
condition controlled loops were combined in order to iteratively
construct GSL structures from their building blocks (ceramide, sia-
lic acid, hexose, N-acetylhexosamine, etc.). A set of rules was
applied to control compliance with the biosynthetically deter-
mined rules. Atomic masses of the most abundant isotopes were
used to calculate the theoretical (monoisotopic) masses of GSL
ions, using ﬁve decimal characters accuracy.
The GSL-ﬁnder MS is created as standalone Windows-based
application for comparing MS data from imported reference list
with the database according to selected search criteria.
The GSL-ﬁnder MSMS is application written in Mathematica 8.0
for correlating obtained tandem MS data with GSL database
according to search criteria. The application requires Mathematica
8.0 or higher. Applications are available from the http://tiny-
url.com/cd56ev6 (full link is provided in supporting data ﬁle).
The installation manual containing instructions for users is pro-
vided together with the GSL-ﬁnder applications on the same web-
page.
3. Results and discussion
3.1. Building a database
GLS database for MS ion search should provide the theoretical
m/z of a candidate structure/molecular formula for comparison to
the actual measuredm/z of an ion within the given mass tolerance.
Accordingly, our database was constructed to provide theoretical
mass of a searched molecular ion ([MH]) followed by the
description of its structure. For in silico generation of GSL struc-
tures, their basic building blocks (a particular ceramide, oligosac-
charide chain and sialic acid/sulfate group) were used. Ceramide
part of a molecule was constructed as a combination of 13 sphing-
oid base variations (including di- and trihydroxylated sphingoid
bases) and 27 fatty acyl residues, giving a total of 351 ceramides.
Hexose (isobaric sugars: galactose and glucose; Hex) and N-ace-
tylhexosamine (HexNAc) were main residues used for generating
the neutral oligosaccharide chain. For GG sialylation status,
Figure 1. Low-energy CID spectrum of O-Ac-GD3 (d18:1/18:0). Product ions
labeled according to: (a) nomenclature proposed by Domon and Costello;39 (b)
GSL-ﬁnder MSMS ion search (the spectrum was manually annotated on a basis of
GSL-ﬁnder MSMS output).N-acetylneuraminic acid (NeuAc), N-glycolylneuraminic acid (Neu-
Gc) and 2-keto-3-deoxynononic acid (KDN) were considered. In
addition to the common GSL building blocks, possible modiﬁca-
tions by fucosylation (Fuc), O-acetylation, de-N-acetylation, sulfa-
tion, attachment of a glucuronic acid (GlcA) residue, repeating
terminal hexose–N-acetylhexosamine– (Hex–HexNAc–)1–6 exten-
sion attachment, and formation of lactone were considered. Data-
base components were created by addition of the building blocks
and subsequent ﬁltering, which checked whether the resulting
GSL is in accordance with the biosynthetic rules. HexNAc units
were restricted to structures containing more than one Hex unit
considering the neutral oligosaccharide chain in structures of gan-
glio-, neolacto-, and lacto-series, and more than two Hex units for
globo- and isoglobo-series. NeuAc unit was restricted to structures
containing one and more Hex residues in the neutral oligosaccha-
ride chain. Other sialic acid (NeuGc, KDN) residues were restricted
to structures containing between one and four Hex units. NeuGc,
KDN and NeuAc were allowed to be combined in the same
structure. O-Ac-, di-O-Ac-, and de-N-Ac-modiﬁcations were
restricted to structures containing at least one sialic acid residue.
HSO3-modiﬁcation was restricted to neutral oligosaccharide
chains, and to chains containing glucuronic acid (GlcA) residue.
Fuc, Hex, HexNAc, and (Hex-HexNAc)1–6 units were considered as
possible additional modiﬁcations when number of Hex units was
greater than two. Lactone formation was restricted to structures
containing at least two sialic acids.
The database also includes neutral GSLs and therefore starts
with the m/z 668, which corresponds to HexCer with the shortest
ceramide (d18:1/14:1). The highest includedm/z is 5000 in order
to cover theoretically possible complex GSL species with multiply
repeating structural motifs, which is important for analysis of GSLs
originating from tumor transformed tissues characterized by
polysialylation and aberrant glycosylation.12,38 Modiﬁcations used
to cover diversity of GSL structures which could possibly occur in
normal and pathological tissues of different organisms, has
resulted in a large number of database constituents (148000
structures). Main ganglio-series gangliosides and corresponding
asialo-species included in the database are: GM1, GD1, GT1, GQ1,
GP1, GH1, GM2, GD2, GT2, GQ2, GM3, GD3, GT3, GQ3, GM4, Gg4
or GA1, Gg3 or GA2, LacCer, and HexCer. Other included GSLs
belong to lacto-, neolacto-, globo-, and isoglobo-series (nLc, Lc,
Gb and iGb, respectively). The complete list of all oligosaccharide
residues with different modiﬁcations and their sialylation/sulfa-
tion status can be found in supporting data ﬁle.
Usually in tandem MS ion search, once candidate sequences are
determined from MS ion search, tandem mass spectrum can be
compared with the expected fragmentation pattern of each candi-
date. The expected fragmentation pattern can be in a form of a
database (of previously sequenced candidates) or can be created
during the matching process. However, we identiﬁed several issues
which affect generation of GSL fragmentation patterns and
increase the search space. The ﬁrst is the biosynthetically deter-
mined occurrence of GG structural isomers that differ according
to the arrangement of sialic acid residues attached along the neu-
tral oligosaccharide chain (e.g., Gal-GalNAc-Gal-Glc-Cer). Sialic
acid residues are mostly linked to the inner or/and terminal Gal
residue (as monosialo-, disialo- or trisialo residue). Therefore, with
increasing number of sialic acid residues in more complex ganglio-
sides, the number of combinations (i.e., isomers) is also increased
making the structural identiﬁcation more complicated. The second
issue is additional complexity enhancement by adding modiﬁca-
tions, especially if the sialic acid residue is modiﬁed, as in the case
of O-acetylation. For example, an O-acetylated GQ1 (O-Ac-GQ1;
four sialic acid residues among which one is O-acetylated) has 20
possible isoforms if structural isomerism of O-acetylated sialic acid
is ignored (position of O-Ac within sialic acid). The third issue is thevariety of product ion types. The negative ion mode fragmentation
of GGs usually involves cleavage of the glycosidic bond. Product
ions can be formed from the oligosaccharide end retaining the
charge on the carbohydrate portion (designated as A, B, and C ions,
according to the systematic nomenclature of glycoconjugate prod-
uct ions39), or they can be formed from the lipid side containing
ceramide residue alone or together with sugar units (designated
as X, Y, and Z ions). The cleavage of the glycosidic bond at the
reducing end of the molecule will produce B or Y ions, while cleav-
age at non-reducing end will produce C or Z ions, respectively.
Therefore, each isoform of an O-Ac-GQ1 has between ﬁve and nine
fragmentation patterns (depending on O-Ac and SA loss) giving all
together 140 patterns for 20 isoforms. However, most of the pat-
terns are not distinctive and O-Ac-GQ1 example has only two pat-
terns with unique isoform identiﬁcation.
In general, negative ion low-energy CID of GG molecular ions
readily display abundant loss of sialic acid moieties and cleavage
of the glycosidic bonds at the reducing end of the molecule. The
released monosialo-fragment is represented by B1, B1a, and/or
B1b product ions, while cleavage of the glycosidic bond with reten-
tion of the glycosidic oxygen atom yields Yn ions. So, the major
product ions (Y- and most of Z-ions) of a glycosphingolipid frag-
mentation pattern are structurally identical to the corresponding
simpler glycosphingolipid species. Therefore, the tandem MS ion
search is simpliﬁed in such a manner that MS ion database is used
for matching tandem MS spectra. As an illustration, O-Ac-GD3
(d18:1/18:0) was fragmented by a low-energy CID (Fig. 1) and
major product ions observed are designated Y3, [Y3-Ac], Y2, B1, B2,
and B2-Ac (Fig. 1a). The same spectrum designated according to
the tandem MS ion search is represented in Figure 1b. The product
ion [MHAc] corresponds to GD3 structure while the ions Y3,
[Y3-Ac], and Y2 correspond to O-Ac-GM3, GM3, and LacCer, respec-
tively. Assignment of the sialic acid fragments was done by using
separately created database with sialic acid residues and their
modiﬁcations (O-acetylation and de-N-acetylation).
Figure 2. Product ion spectra of the double charged ions at m/z 917.5 (a) and 931.5
(b) corresponding to GD1a (d18:1/18:0) and GD1a (d18:1/20:0) or (d20:1/18:0),
respectively. The spectra were manually annotated on a basis of GSL-ﬁnder MSMS
output.3.2. Database searching
GSL-ﬁnder applications (MS and MSMS) are designed to com-
pare the experimental data with the database. To create a list of
ions m/z values intended to be searched against the GSL-ﬁnder
database, experimentally obtained MS and/or tandem MS data
should be preformatted in such way that all multiply charged ions
are deconvoluted to singly charged negative ions. One can consider
to eliminate noise from the spectrum as well as to reduce the num-
ber of ions. At the moment program does not take into account ion
intensities and the search list should contain only the ionsm/z val-
ues. The requirement for the candidate MS ion search list is that
each ion should be written in a separate line. For the MSMS ion
search list, a precursor ion mass should be followed by the masses
of its product ions in the same line. Next precursor ion together
with the masses of its product ions should follow in a new line.
Prior to MS or MSMS database search, a desired mass tolerance
(Dm) should be deﬁned. A user can also exclude some or all struc-
tural modiﬁcations: fucosylation (Fuc), O-acetylation, de-N-acety-
lation, sulfation, attachment of hexose–N-acetylhexosamine
(Hex–HexNAc) or glucuronic acid (GlcA) residues, and presence
of lactone. At the completion of the MS ion search the GSL-ﬁnder
MS provides a list of GSLs that match the measured mass. Each out-
put on the list contains the following information: measured mass,
theoretical mass, difference between the experimental and calcu-
lated masses, name of the theoretical GSL. The matched measured
mass is a prerequisite for MSMS ion search where the results are
ranked on a basis of the highest score. Tandem MS scoring is based
on a number of the diagnostic ions from the database that match
ions observed in the spectrum. Each ranked GSL also contains
information about experimental and theoretical mass, difference
between the experimental and calculated masses, name of the the-
oretical GSL, number and type of matched sialic acid residues
(including modiﬁed sialic acid moieties), structure of Y- and Z-ions
according to the basic building blocks.
3.3. Limitations of the database and database searching
Developed database and GSL-ﬁnder applications hold some con-
strains which potential user has to have in mind. (I) As already
mentioned above, spectra processing is not performed by GSL-ﬁn-
der applications. Spectra need to be preprocessed and all multiply
charged ions deconvoluted to the singly charged deprotonated
ions. (II) Database and GSL-ﬁnder applications are tuned for
negative ion mode. According to available literature data and our
own experimental experience gangliosides and sulfo-glyco-
sphingolipids ionize more readily in the negative versus positive
ion mode.40,41 (III) At present, the GSL-ﬁnder MSMS application
do not assign cross-ring cleavage product ions since the MS ion
database is used for matching tandem MS spectra, vide supra.
(IV) Monosaccharide isomers, Glc versus Gal and GlcNAc versus
GalNAc, cannot be distinguished, nor can consequently be distin-
guished two or more analogous oligosaccharide residues differing
by these monosaccharide units (e.g., Gg3 vs Lc3). (V) Isomeric cer-
amide structures cannot be distinguished. The GSL-ﬁnder MS and
MSMS search results give the most probable (common) naturally
occurring ceramide structures/isomers, corresponding to the
selected m/z value, in the form sphingoid base/fatty acid. The pro-
vided sphingoid base and fatty acid residue structures, although
the most probable, are tentative, and could be conﬁrmed only by
further MS sequencing of the ceramide ion. (VI) Due to the high
diversity of GSL structures present in the database, GSL-ﬁnder
MSMS search results may contain considerable rate of false
positive suggestions. False positive suggestions were deﬁned as
incorrectly identiﬁed GSL species with a higher score than a true
positive. The rate of the false positive suggestions for GSL mixturesused for testing and validation of the database was around 19.6%.
However, this can be reduced by deﬁning possible structural mod-
iﬁcations, types of sialic acids and ceramides prior to search
against database. An ‘educated guess’ about the sample type is
desirable, for example, gangliosides from human tissue samples
lack NeuGc sialic acids and contain mainly ceramides with even
number of carbon atoms. Moreover, one should eliminate or at
least very carefully evaluate a search result suggesting an acety-
lated ganglioside without signals that correspond to the acetylated
sialic acid moiety. Having all that in mind, a rate of the false posi-
tive suggestions for tested GSL mixtures was reduced to 6%.
3.4. Testing and validation of the database
In order to test and validate the GSL-ﬁnder application and the
database, we have applied it to the analysis of several GSL mixtures
from different biomaterial: the puriﬁed GD1a ganglioside fraction
from bovine brain, complex ganglioside mixtures from both fetal
and adult human brain, as well as complex ganglioside mixture
from calf brain. Additionally, we have recently successfully applied
the GSL-ﬁnder to the analysis of brain gangliosides from mice with
altered ganglioside biosynthesis.42
3.4.1. GD1a ganglioside fraction
The most abundant signals in MS spectra of the GD1a ganglio-
side fraction from bovine brain were doubly charged negative ions
at m/z 917.5 and 931.5, respectively. The ions were selected and
fragmented by low-energy CID (Fig. 2). A range of product ions
were produced representing cleavages of glycosidic bonds. In order
to perform structural identiﬁcation (and validation of the GSL-ﬁn-
der database), all multiply charged ions were deconvoluted to sin-
gly charged ions and the ion list was created following the
requirements for MSMS ion search list.
MSMS database search of the product ions obtained from the
double charged molecular ion at m/z 917.5 returned two species
with the highest score: GD1 (d18:1/18:0) and GD1 (t18:1/17:1);
complete search results can be found in supporting data ﬁle. Both
species have the same number of the diagnostic ions matching the
Table 1
Ganglioside composition of the fetal human brain in 13th g.w., as obtained by matching experimental MS data with the GSL-ﬁnder MS and MSMS database search
Experimental (m/z) Mass accuracy (ppm) Proposed structurea
857.55 37 Phosphatidylinositol (36:4)b
883.55 23 Phosphatidylinositol (38:5)b
885.58 33 Phosphatidylinositol (38:4)b
1151.60 92 GM3 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1179.70 32 GM3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1253.80 21 GA1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1261.80 12 GM3 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .
1382.80 12 GM2 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1442.60 140 GD3 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1470.79 29 GD3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1516.69 98 GM1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1542.90 30 GM1 (d18:1/18:1) or (d20:1/16:1) or (d22:1/14:1) or (d16:1/20:1). . .
1544.80 45 GM1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1572.80 64 GM1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1626.77 109 GM1 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .
1645.69 116 GD2 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1673.77 85 GD2 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1701.80 84 GD2 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1807.78 85 GD1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1833.86 49 GD1 (d18:1/18:1) or (d20:1/16:1) or (d22:1/14:1) or (d16:1/20:1). . .
1835.82 79 GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1849.79 83 OAc GD1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1857.71Na 127 GD1 (d18:1/18:0) or (d20:1/16:0). . .+Na
1863.83 89 GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1891.90 67 GD1 (d18:1/22:0) or (d20:1/20:0) or (d22:1/18:0) or (d24:1/16:0). . .
1893.86 97 GD1 (d18:0/22:0) or (d20:0/20:0) or (d22:0/18:0) or (d24:0/16:0). . .
1917.98 33 GD1 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .
1919.96 51 GD1 (d18:1/24:0) or (d20:1/22:0) or (d22:1/20:0) or (d24:1/18:0). . .
2098.89 66 GT1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
2124.89 73 GT1 (d18:1/18:1) or (d20:1/16:1) or (d22:1/14:1) or (d16:1/20:1). . .
2126.88 85 GT1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
2148.92Na 57 GT1 (d18:1/18:0) or (d20:1/16:0). . .+Na
2208.89 112 GT1 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .
2200.91 85 (Hex-HexNAc) GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0). . .
a Only most likely ceramide residues are shown. Other possible ceramide combinations can be found in Supporting information Table 1-SI.
b Structures assigned manually; phospholipids are not included in the database.ions observed in the fragmentation spectrum, because their cera-
mides have similar molecular masses (0.0364 l mass difference).
However, knowing that GD1 (d18:1/18:0) predominates in mam-
malian (i.e., bovine) brain tissue,43,44 we can assume that frag-
mented ion was GD1 (d18:1/18:0). Finally, considering the
absence of the ion at m/z 581 (Fig. 2a), which corresponds to [Neu-
Ac–NeuAc-H], and having highly abundant ion at m/z 290 ([Neu-
Ac-H]), we can conclude that the analyzed isomer was GD1a.
MSMS ion search of the product ions obtained from the double
charged molecular ion atm/z 931.5 also identiﬁed two species with
the highest score: GD1 (d18:1/20:0) or (d20:1/18:0) and GD1
(t18:1/19:1); complete search results can be found in supporting
data ﬁle. GSLs with even numbered sphingoid bases and fatty acid
residues are much more abundant in mammalian brain tissue than
odd numbered, which are only present in traces in bovine brain tis-
sue.41,45 While sphingosine (d18:1) predominates, the sphingoid
base d20:1 is also quite abundant in GSLs of mammalian nervous
system.44 Therefore, we believe that fragmented ion was GD1
(d18:1/20:0) or (d20:1/18:0), and also belonging to a-series of gan-
gliosides due to the absence ofm/z 581 product ion, while showing
highly abundant ion at m/z 290 corresponding to NeuAc residue
(Fig. 2b).
3.4.2. Native ganglioside mixtures from human and calf brain
tissue
To test the GSL-ﬁnder on ‘real life’ samples, a native ganglioside
mixture isolated from fetal human brain (13th gestational week,
g.w.), adult human brain (54 years), and calf brain tissue were
analyzed.3.4.3. Fetal human brain gangliosides analysis
The MS scan contained a total of 40 signals (Fig. 1-SI in Supple-
mentary material). Due to the difﬁculty to isolate and fragment the
low abundance ions, only signals above 2% relative intensity were
subjected to tandem MS. All acquired tandem MS spectra were
combined and searched against GSL-ﬁnder database. The list of can-
didate gangliosides produced by GSL-ﬁnder was additionally re-
evaluated in a way that:
 ceramides with even numbered sphingoid bases and fatty
acids are preferred, vide supra;
 acetylated gangliosides without signals that correspond to
acetylated sialic acid moiety, are ignored;
 gangliosides with greater number of Y-ions are preferred.
The ﬁnal search results are shown in Table 1. Complete results
of the analysis are summarized in Table 1-SI in Supporting infor-
mation. Obtained structures from Table 1 were compared with pre-
viously reported (manually interpreted) ganglioside analysis of
human fetal hippocampi (15 and 17 g.w.).25 The brain samples
showed high resemblance in general GG pattern, sharing all com-
mon ganglioside species characteristically present in fetal human
brain (GM3, GM2, GD3, GD2, GM1, GD1, GT1). Signals with highest
intensity in all brain tissues samples correspond to GD1 (d18:1/
18:0) and GT1 (d18:1/18:0). Differences related to the charge
states and frequency of sodiated species are attributed to the dif-
ferent MS instruments used. Small alteration in GG species compo-
sition and differences in individual GG abundances (e.g., higher
abundance of GD3 and higher diversity of GD1 and GT1 species
Table 2
Ganglioside composition of the adult human brain (54 years), as obtained by matching experimental MS data with the GSL-ﬁnder MS
Experimental (m/z) Mass accuracy (ppm) Proposed structurea
788.60 63 Phosphatidylserine (36:1)b
806.66 124 Phosphatidylserine (38:6)b
816.60 245 Phosphatidylserine (38:1)b
835.56 36 Phosphatidylinositol (34:1)b
857.54 23 Phosphatidylinositol (36:4)b
861.68 151 Phosphatidylinositol (36:2)b
878.62 23 HSO3-Hex-Cer (t18:1/22:0) or (d18:1/h22:0) or (t18:0/22:1). . .
883.55 23 Phosphatidylinositol (38:5)b
885.58 33 Phosphatidylinositol (18:0/20:4) = (38:4)b
888.64 18 HSO3-Hex-Cer (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1). . .
892.66 6 HSO3-Hex-Cer (d18:0/24:0) or (d20:0/22:0) or (d22:0/20:0). . .
902.66 63 HSO3-Hex-Cer (d18:1/25:1) or(t18:1/24:2) or (d18:1/h24:2)
904.70 50 HSO3-Hex-Cer (d18:1/25:0) or (d20:1/23:0). . .
906.68 31 LacCer (t18:0/18:0)
1179.76 17 GM3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1207.78 8 GM3 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1382.75 51 GM2 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1410.75 71 GM2 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1470.86 20 GD3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1498.81 31 GD3 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1516.74 66 GM1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1542.92 45 GM1 (d18:1/18:1) or (d20:1/16:1) or (d22:1/14:1) or (d16:1/20:1). . .
1544.76 71 GM1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1572.78 76 GM1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1600.93 1 GM1 (d18:1/22:0) or (d20:1/20:0) or (d22:1/18:0) or (d24:1/16:0). . .
1673.76 90 GD2 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1702.35 241 GD2 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1836.03 38 GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1857.68Na 145 GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .+Na
1863.71 156 GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1878.36 205 OAc GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1892.93 106 GD1 (d18:1/22:0) or (d20:1/20:0) or (d22:1/18:0) or (d24:1/16:0). . .
1899.94 47 GD1 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .H2O
1906.08 37 OAc GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1920.08 10 GD1 (d18:1/24:0) or (d20:1/22:0) or (d22:1/20:0) or (d24:1/18:0). . .
1921.96 57 GD1 (d18:0/24:0) or (d20:0/22:0) or (d22:0/20:0) or (d24:0/18:0). . .
2038.87 83 (HexNAc) GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0). . .
2067.11 15 (HexNAc) GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0). . .
2127.01 24 GT1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
2148.91Na 60 GT1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .+Na
2155.07 9 GT1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
2176.89Na 83 GT1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .+Na
2168.89 83 OAc GT1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
2183.01 50 GT1 (d18:1/22:0) or (d20:1/20:0) or (d22:1/18:0) or (d24:1/16:0). . .
2192.67 241 GT1 (d18:1/24:0) or (d20:1/22:0) or (d22:1/20:0) or (d24:1/18:0). . .H2O
2197.21 50 OAc GT1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
2209.08 27 GT1 (d18:1/24:1) or (d20:1/22:1) or (d22:1/20:1) or (d24:1/18:1). . .
2218.97 86 GT1 (d18:1/26:1) or (d20:1/24:1) or (d22:1/22:1) or (d24:1/20:1). . .H2O
a Only most likely ceramide residues are shown.
b Structures assigned manually; phospholipids are not included in the database.in 13th g.w. fetal brain) could be due to difference in analyzed
brain regions as well as due to small differences in developmental
age of the analyzed fetal brains.11 Overall, the obtained data are
consistent with previous studies and could argue the credibility
and reliability of our new developed ganglioside database.
3.4.4. Adult human brain ganglioside analysis
A native ganglioside mixture isolated from adult human brain
cortex (54 years) was analyzed in accordance with the data analy-
sis principle previously explained, vide supra. The ﬁnal search
results are shown in Table 2. The adult brain sample showed all
common ganglioside species usually present in adult human
brain46 (highly abundant structurally complex gangliosides GM1,
GD1, GT1, and less abundant simple gangliosides GM3, GM2,
GD3, GD2), as well as O-acetylated GD1 and GT1 gangliosides
and sulfatides, which were previously not detected in fetal human
brain. The highest intensity signal corresponds to GD1 (d20:1/
18:0) and second highest to GT1 (d20:1/18:0), which correlates
with previously reported higher ratio of d20/d18-sphingoid basesin adult human brain, opposite from the ratio in fetal human
brain.44 Altogether, 34 different ganglioside structures, 5
sulfatides, and 1 neutral GSL species were characterized in the
analyzed mixture from adult human brain cortex, which is 19
structures more than previously identiﬁed (manually interpreted)
in ganglioside mixture isolated from adult human hippocampus
(20 years).25
3.4.5. Calf brain ganglioside analysis
Results of the analysis of ganglioside mixture isolated from calf
brain are summarized in Table 3. The calf brain sample displayed
all common ganglioside species characteristically present in adult
human brain (GM1, GD1, GT1, GM3, GM2, GD3, and O-Ac-GD1).
Moreover, an additional O-Ac-GD1 ganglioside containing one
NeuGc-residue (instead of NeuAc-residue) was detected. As evi-
denced, NeuGc-containing glycans rarely occur in the brain of ver-
tebrates, and are absent in human brain.47 Altogether, in the
analyzed mixture from calf brain, 16 ganglioside structures, 1 sul-
fatide, and 3 neutral GSL species were identiﬁed.
Table 3
Ganglioside composition of calf brain tissue, as obtained by matching experimental MS data with the GSL-ﬁnder MS and MSMS database search
Experimental (m/z) Mass accuracy (ppm) Proposed structurea
806.65 111 Phosphatidylserine (38:6)b
822.55 11 HSO3-Hex-Cer (t18:1/18:0) or (t18:0/18:1)
857.68 187 Phosphatidylinositol (36:4)b
862.70 86 LacCer (d18:0/16:0) or (d20:0/14:0) or (d16:0/18:0)
885.65 113 Phosphatidylinositol (18:0/20:4) = (38:4)b
890.68 25 LacCer (d18:0/18:0) or (d20:0/16:0) or (d22:0/14:0) or (d16:0/20:0)
906.69 42 LacCer (t18:0/18:0)
1179.58 133 GM3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1382.80 12 GM2 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1410.93 58 GM2 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1470.80 22 GD3 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1516.80 25 GM1 (d18:1/16:0) or (d20:1/14:0) or (d18:0/16:1) or (d20:0/14:1). . .
1544.89 13 GM1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1572.91 6 GM1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1835.98 8 GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1877.96 8 OAc GD1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
1892.00 14 GD1 (d18:1/22:0) or (d20:1/20:0) or (d22:1/18:0) or (d24:1/16:0). . .
1905.99 9 OAc GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
1921.94 32 OAc GD1 (NeuAcNeuGc) (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0). . .
1931.78 125 GD1 (t18:1/24:2)
2067.06 28 (HexNAc) GD1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0). . .
2127.01 24 GT1 (d18:1/18:0) or (d20:1/16:0) or (d22:1/14:0) or (d18:0/18:1). . .
2149.02Na 13 GT1 (d18:1/18:0) or (d20:1/16:0). . .+Na
2155.06 15 GT1 (d18:1/20:0) or (d20:1/18:0) or (d22:1/16:0) or (d24:1/14:0). . .
2177.07Na 11 GT1 (d18:1/20:0) or (d20:1/18:0). . .+Na
a Only most likely ceramide residues are shown.
b Structures assigned manually; phospholipids are not included in the database.4. Conclusions
Presented computationally created database of GSL species ions
and GSL-ﬁnder application provide a simple and automated routine
for the GSL identiﬁcation via MS and/or MSMS ion search. The
database contains ganglioside and sulfo-GSL structures, as well as
their neutral counterparts, with high diversity of ceramide compo-
sitions, sialic acid structures, and possible additional substitutions
(modiﬁcations), including those proposed to occur in pathologi-
cally changed biomaterial (e.g., tumors).
The GSL-ﬁnderMSMS application takes full advantage of the fact
that major product ions (Y- and Z-ions) of a GSL fragmentation pat-
tern are structurally identical to the corresponding simpler GSL/
ceramide species, so accordingly simpliﬁes a tandemMS ion search
by using the MS ion database for matching tandem MS spectra.
Validation results showed consistency with previous studies, vast
improvement in speed over manual interpretation taking into
account that the data can be quickly re-analyzed choosing different
parameters.
In summary, newly developed database and application facili-
tate negative ion mass spectrometric analysis of complex glyco-
sphingolipid mixtures isolated from various healthy and
pathological biomaterials (tissues, cell cultures, body ﬂuids, etc.).
Nomenclature section
The abbreviated designation of carbohydrates and glyco-
sphingolipids follows the recommendations of IUPAC-IUB Commis-
sion on Biochemical Nomenclature48,49 and gangliosides are
abbreviated according to the systemof Svennerholm50,51 as follows:
LacCer, Galb4Glcb1Cer; GA2, Gg3Cer, GalNAcb4Galb4Glcb1Cer;
GA1, Gg4Cer, Galb3GalNAcb4Galb4Glcb1Cer; Lc3, GlcNAcb3Galb
4Glcb1Cer; Lc4, Galb3GlcNAcb3Galb4Glcb1Cer; nLc4, Galb4Glc-
NAcb3Galb4Glcb1Cer; nLc6, Galb4GlcNAcb3Galb4GlcNAcb3Galb
4Glcb1Cer; Gb3, Gala4Galb4Glcb1Cer; Gb4, GalNAcb3Gala4Galb4
Glcb1Cer; iGb3, Gala3Galb4Glcb1Cer; iGb4, GalNAcb3Gala3Galb
4Glcb1Cer; GM3, II3-a-Neu5Ac-LacCer; GD3, II3-a-(Neu5Ac)2-LacCer;GT3, II3-a-(Neu5Ac)3-LacCer; GM2, II3-a-Neu5Ac-Gg3Cer; GD2,
II3-a-(Neu5Ac)2-Gg3Cer; GM1a or GM1, II3-a-Neu5Ac-Gg4Cer;
GM1b, IV3-a-Neu5Ac-Gg4Cer; GalNAc-GM1b, IV3-a-Neu5Ac-Gg5
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